In a recent publication by Orrick, Herrington & Sutcliffe LLP titled “Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2023”, an examination of quarterly trends in life sciences venture investment presents notable insights. The report notes an increase in the value of deals in Q3 2023, reflected in the $7.7 billion total, despite a decrease in the number of deals.
This development is significant, seeing that total deal value has consistently grown each quarter in 2023, reaching a year-to-date (YTD) total of $21.4 billion. Although this indicates a thriving sector, a glance at the preceding year suggests that there is still some ground to cover. By the same stage in 2022, deal values had reached a staggering $28.9 billion.
The firm’s full publication offers more details about these trends and other aspects on life sciences venture investment. While current observations point towards a slow yet steady recovery, the implications of this on future investment and the overall health of the life sciences sector remain to be decisively gauged.